Eledon Pharmaceuticals
Market cap $167M 84.5M shares (10-Q, Nov 10, 2026) × $1.98 close Nov 17, 2026
Most recent annual filing: 2026-03-19
- Tegoprubart kidney Ph3 startlate 2026Tegoprubart kidney Ph3 start, late 2026, notable
- LEGACY Phase 3 Ph3 start4Q 2026LEGACY Phase 3 Ph3 start, 4Q 2026, routine
- Eledon financing2Q 2027Eledon financing, 2Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Discontinued (1)
- tegoprubart — IgA Nephropathy · deprioritized; all IgAN clinical development activities were discontinued in 2023
Capital (as filed)
- Cash
- $6.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $62.8M Sep 30, 2026
- Operating cash flow
- −$19.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $69.7M cash, runway Q2 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
- 2026-11-13 UPDATE: Eledon Pharmaceuticals (ELDN) - The Phase 3 Waits on the Wallet 🔒 Paid
- 2026-09-23 UPDATE: Eledon Pharmaceuticals (ELDN) - The 24-Month Curves Keep Separating 🔒 Paid
- 2026-09-03 UPDATE: Eledon Pharmaceuticals (ELDN) - The Islet Program Grows Up 🔒 Paid
- 2026-08-14 Eledon Pharmaceuticals (ELDN) — Scientific Deep Dive for Tegoprubart and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Eledon Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-14 Watch Eledon Pharmaceuticals (ELDN) — Scientific Deep Dive for Tegoprubart and Pipeline Products Despite compelling biology and tolerability differentiation, a missed Phase 2 primary endpoint, undisclosed Phase 3 NI margin, and unfunded trial behind a going-concern conclusion leave too many unresolved questions to open a position.
- 2026-09-03 Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The Islet Program Grows Up Islet IND filing converts the most under-modeled asset into a company-owned registrational path, but the undisclosed NI margin, going-concern conclusion, and worsening dilution math keep the stance at Watch.
- 2026-09-23 Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The 24-Month Curves Keep Separating A 13-point eGFR advantage at 24 months and zero BPAR past six months strengthen the mechanistic story, but the undisclosed NI margin, completer-only analysis, and unresolved going-concern keep the stance at Watch ahead of the financing.
- 2026-11-13 Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The Phase 3 Waits on the Wallet LEGACY's Q4 start is now formally contingent on financing, cash has fallen to $69.7M with $20.7M in committed manufacturing obligations, and a $150M raise at current prices implies ~53% dilution — the raise remains the event to engage around, not ahead of.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseEledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q reveals cash has dropped to $69.7M with a visibly accelerating burn rate — and manufacturing costs alone nearly doubled year-over-year — while the FDA cleared the islet IND and BVF quietly converted another slug of preferred to common. The financing window is tighter than the headline runway implies.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 26, 2026ReleaseEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology
- Oct 5, 2026ReleaseEledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
- Sep 22, 2026ReleaseEledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society→ BD updateEledon just received FDA Fast Track Designation for tegoprubart and presented BESTOW extension data showing the eGFR advantage vs. tacrolimus growing to ~13 mL/min/1.73m² at month 24 with statistical significance — and zero rejections in the tegoprubart arm beyond month six. The three-point delta that underwhelmed at month 12 appears to be compounding, not fading.BD extracted 1 program update from this document → ELDN pipeline
- Sep 9, 2026ReleaseEledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
- Sep 3, 2026ReleaseEledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial→ BD updateEledon just checked one of my three explicit "add only on" boxes — the company-sponsored islet IND is filed — while simultaneously confirming Q4 2026 LEGACY Phase 3 initiation and opening compassionate-use programs in two new patient populations. The stock is down ~21% from my writeup price, which makes the timing matter.BD extracted 1 program update from this document → ELDN pipeline
- Aug 13, 2026ReleaseEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlightsvia aggregator
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Jun 22, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- May 1, 2026S-3Shelf registration
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1
- Mar 19, 202610-KAnnual report
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Oct 30, 2026SCHEDULE 13G/A13G amendment
- Sep 4, 2026S-8Employee plan registration
- Jul 31, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 11, 2026EFFECTRegistration effective
- May 7, 2026UPLOADUPLOAD
- May 7, 2026CORRESPCORRESP
- Apr 30, 2026ARSAnnual report to shareholders
- Apr 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 21, 2026PRE 14APRE 14A
- Mar 26, 2026SCHEDULE 13G/A13G amendment